[go: up one dir, main page]

CN114835655A - Method for synthesizing optically active trifluoromethyl acrylate compound - Google Patents

Method for synthesizing optically active trifluoromethyl acrylate compound Download PDF

Info

Publication number
CN114835655A
CN114835655A CN202210393810.2A CN202210393810A CN114835655A CN 114835655 A CN114835655 A CN 114835655A CN 202210393810 A CN202210393810 A CN 202210393810A CN 114835655 A CN114835655 A CN 114835655A
Authority
CN
China
Prior art keywords
optically active
trifluoromethacrylate
reaction
catalyst
synthesizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210393810.2A
Other languages
Chinese (zh)
Inventor
朱博
孙慧丽
余永美
张涛
常俊标
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Normal University
Original Assignee
Henan Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Normal University filed Critical Henan Normal University
Priority to CN202210393810.2A priority Critical patent/CN114835655A/en
Publication of CN114835655A publication Critical patent/CN114835655A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36One oxygen atom
    • C07D263/42One oxygen atom attached in position 5
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0255Phosphorus containing compounds
    • B01J31/0267Phosphines or phosphonium compounds, i.e. phosphorus bonded to at least one carbon atom, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, the other atoms bonded to phosphorus being either carbon or hydrogen
    • B01J31/0268Phosphonium compounds, i.e. phosphine with an additional hydrogen or carbon atom bonded to phosphorous so as to result in a formal positive charge on phosphorous
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0271Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds also containing elements or functional groups covered by B01J31/0201 - B01J31/0231
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/50Organo-phosphines
    • C07F9/5022Aromatic phosphines (P-C aromatic linkage)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/50Organo-phosphines
    • C07F9/505Preparation; Separation; Purification; Stabilisation
    • C07F9/5054Preparation; Separation; Purification; Stabilisation by a process in which the phosphorus atom is not involved
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/44Allylic alkylation, amination, alkoxylation or analogues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种合成光学活性三氟甲基丙烯酸酯类化合物的方法,属于有机化学中技术领域。以MBH碳酸酯和噁唑酮为起始原料,在L‑叔亮氨酸和环己基衍生手性双官能团叔胺脲‑膦酰胺/酯类催化剂存在下,经过烯丙基烷基化反应,得到高光学活性的三氟甲基丙烯酸酯类化合物。本发明反应过程对映选择性优异,无需使用过渡金属或化学计量氧化剂;反应原料易得,催化剂结构简单,催化效率高,反应条件温和,后处理简单。The invention discloses a method for synthesizing optically active trifluoromethacrylate compounds, belonging to the technical field of organic chemistry. Using MBH carbonate and oxazolone as starting materials, in the presence of L-tertiary leucine and cyclohexyl-derived chiral bifunctional tertiary amine urea-phosphonamide/ester catalyst, through allyl alkylation reaction, A highly optically active trifluoromethacrylate compound is obtained. The reaction process of the invention has excellent enantioselectivity, does not need to use transition metals or stoichiometric oxidants; the reaction raw materials are readily available, the catalyst structure is simple, the catalytic efficiency is high, the reaction conditions are mild, and the post-treatment is simple.

Description

一种合成光学活性三氟甲基丙烯酸酯类化合物的方法A kind of method for synthesizing optically active trifluoromethacrylate compounds

技术领域technical field

本发明属于有机化学中的不对称合成技术领域,具体涉及合成三氟甲基丙烯酸酯类化合物的方法。The invention belongs to the technical field of asymmetric synthesis in organic chemistry, and particularly relates to a method for synthesizing trifluoromethacrylate compounds.

背景技术Background technique

作为合成含有手性三氟甲基丙烯酸酯类化合物的重要方法,在过去的几十年中进行了广泛研究。在母体分子中引入全氟烷基官能团会显著影响其化学、物理和生物性质,已知的许多含有三氟甲基的手性分子具有重要的要用价值。As an important method for the synthesis of chiral trifluoromethacrylate-containing compounds, it has been extensively studied in the past few decades. The introduction of perfluoroalkyl functional groups into the parent molecule can significantly affect its chemical, physical, and biological properties, and many of the known chiral molecules containing trifluoromethyl groups are of great utility.

许多药物分子的手性部位都含有立体三氟甲基基团,构建含有立体三氟甲基为中心的化合物仍然是目前的研究热点。因此开发经济有效合成光学活性三氟甲基丙烯酸酯类化合物的方法显得非常重要。The chiral parts of many drug molecules contain stereotrifluoromethyl groups, and the construction of compounds containing stereotrifluoromethyl groups is still a research hotspot. Therefore, it is very important to develop a cost-effective method for synthesizing optically active trifluoromethacrylates.

发明内容SUMMARY OF THE INVENTION

为了克服上述技术缺陷,本发明提供了以简单的起始原料合成具有光学活性的三氟甲基丙烯酸酯类化合物的方法。以MBH碳酸酯为起始原料,接着在手性双官能团叔胺脲-膦酯类催化剂存在下,与噁唑酮经过不对烯丙基烷基化反应,合成光学活性三氟甲基丙烯酸酯类化合物。In order to overcome the above technical defects, the present invention provides a method for synthesizing optically active trifluoromethacrylate compounds with simple starting materials. Optically active trifluoromethacrylates were synthesized using MBH carbonate as the starting material, followed by non-allyl alkylation with oxazolone in the presence of a chiral bifunctional tertiary amine urea-phosphonate catalyst. compound.

基于上述目的,本发明采用以MBH碳酸酯1和噁唑酮2为起始原料,接着以手性双官能团叔胺脲-膦酯类化合物作为催化剂,经过不对称烯丙基烷基化反应,以高产率,高对映选择性合成光学活性三氟甲基丙烯酸酯类化合物。Based on the above purpose, the present invention uses MBH carbonate 1 and oxazolone 2 as starting materials, and then uses a chiral bifunctional tertiary amine urea-phosphonate compound as a catalyst to undergo asymmetric allyl alkylation reaction, Synthesis of optically active trifluoromethacrylates with high yield and high enantioselectivity.

一种光学活性三氟甲基丙烯酸酯类化合物的合成方法,包括如下步骤:以 MBH碳酸酯1和噁唑酮2为原料,在L-叔亮氨酸衍生手性双官能团叔胺脲-膦类催化剂存在下,经过不对称烯丙基烷基化反应,得到三氟甲基丙烯酸酯类化合物3。A method for synthesizing an optically active trifluoromethacrylate compound, comprising the steps of: using MBH carbonate 1 and oxazolone 2 as raw materials, derivatizing a chiral bifunctional tertiary amine urea-phosphine in L-tertiary leucine In the presence of such a catalyst, the trifluoromethacrylate-based compound 3 is obtained through asymmetric allyl alkylation reaction.

反应方程式如下:The reaction equation is as follows:

Figure RE-GDA0003704228850000011
Figure RE-GDA0003704228850000011

其中:R1选自卤素、C1-C4烷基、C1-C4烷氧基、噻吩基;R2选自C1-C4烷基。Wherein: R 1 is selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, thienyl; R 2 is selected from C1-C4 alkyl.

进一步地,在上述技术方案中,R1选自2-F、3-Me、2-噻吩基、3-噻吩基; R2选自Me、Et。Further, in the above technical solution, R 1 is selected from 2-F, 3-Me, 2-thienyl, and 3-thienyl; R 2 is selected from Me, Et.

进一步地,在上述技术方案中,催化剂选自C1-C8,具体结构式如下:Further, in the above-mentioned technical scheme, the catalyst is selected from C1-C8, and the specific structural formula is as follows:

Figure RE-GDA0003704228850000021
Figure RE-GDA0003704228850000021

进一步地,在上述技术方案中,催化剂优选自C1或C6。Further, in the above technical solution, the catalyst is preferably selected from C1 or C6.

进一步地,在上述技术方案中,所述MBH碳酸酯1、噁唑酮2与催化剂摩尔比为1:1-1.5:0.05-0.10;优选摩尔比为1:1.5:0.10。Further, in the above technical solution, the molar ratio of the MBH carbonate 1, the oxazolone 2 and the catalyst is 1:1-1.5:0.05-0.10; the preferred molar ratio is 1:1.5:0.10.

进一步地,在上述技术方案中,反应温度为0-30℃,优选25℃。Further, in the above technical solution, the reaction temperature is 0-30°C, preferably 25°C.

进一步地,在上述技术方案中,反应在空气氛围下进行。Further, in the above technical solution, the reaction is carried out in an air atmosphere.

进一步地,在上述技术方案中,反应在有机溶剂中进行,反应溶剂选自甲苯、二氯甲烷、四氢呋喃、均三甲苯、氯苯、五氟苯、间二甲苯、邻二甲苯或乙醚;优选反应溶剂为甲苯。Further, in the above-mentioned technical scheme, the reaction is carried out in an organic solvent, and the reaction solvent is selected from toluene, dichloromethane, tetrahydrofuran, mesitylene, chlorobenzene, pentafluorobenzene, m-xylene, o-xylene or ether; preferably The reaction solvent is toluene.

发明有益效果:Invention Beneficial Effects:

本发明以MBH碳酸酯为起始原料与噁唑酮的不对称烯丙基烷基化反应一锅得到光学三氟甲基丙烯酸酯类化合物,原料简单易得,催化剂结构简单/催化效率高,反应条件温和,后处理简单,催化剂可回收再利用,产物收率、对映选择性良好至优秀。The invention takes MBH carbonate as a starting material and asymmetric allyl alkylation of oxazolone to obtain optical trifluoromethacrylate compounds in one pot, the raw materials are simple and easy to obtain, the catalyst structure is simple and the catalytic efficiency is high, The reaction conditions are mild, the post-treatment is simple, the catalyst can be recycled and reused, and the product yield and enantioselectivity are good to excellent.

具体实施方式Detailed ways

以下结合具体实施例对本发明的技术方案作进一步详细说明,但本发明的保护范围并不局限于此。The technical solutions of the present invention will be described in further detail below with reference to specific embodiments, but the protection scope of the present invention is not limited thereto.

反应条件的考察Investigation of reaction conditions

典型操作如下:将Morita-Baylis-Hillman碳酸酯1(0.1mmol,1.0eq和催化剂C1(0.76mg,0.01mmol,0.1eq)溶解在超干甲苯(1.0mL)中,然后将4-叔丁基-2-三氟甲基噁唑-5(2H)-酮2(0.15mmol,1.5eq)。将反应混合物在室温搅拌72h,并通过TLC监测。待原料完全反应后,将反应混合物直接在短硅胶柱上PE/EA=50:1-20:1梯度洗脱得到产物。A typical procedure was as follows: Morita-Baylis-Hillman carbonate 1 (0.1 mmol, 1.0 eq and catalyst C1 (0.76 mg, 0.01 mmol, 0.1 eq) were dissolved in ultra-dry toluene (1.0 mL) followed by 4-tert-butyl -2-Trifluoromethyloxazol-5(2H)-one 2 (0.15 mmol, 1.5 eq). The reaction mixture was stirred at room temperature for 72 h and monitored by TLC. After the complete reaction of the starting materials, the reaction mixture was directly The product was obtained by gradient elution of PE/EA=50:1-20:1 on a silica gel column.

Figure RE-GDA0003704228850000031
Figure RE-GDA0003704228850000031

a反应条件:1(0.1mmol),2(0.15mmol),催化剂(0.01mmol),超干甲苯(1.0mL),25℃。b通过快速柱层析得到产率。c通过高效液相测得ee,d通过1H NMR谱测到d.r.。 a Reaction conditions: 1 (0.1 mmol), 2 (0.15 mmol), catalyst (0.01 mmol), ultra-dry toluene (1.0 mL), 25°C. b Yield by flash column chromatography. c ee by HPLC, d dr by 1 H NMR spectroscopy.

在反应条件筛选过程中,首先考察了不同催化剂对反应的影响(entries 1-8),最终确定了催化剂C1为最佳催化剂,在C2催化剂作用下,得到是α-烯丙基烷基化产物,然后考察了溶剂对反应的影响(entries 9-12),最终确定了无水甲苯为最佳溶剂,反应温度为25℃,催化剂用量为10mol%。During the screening of reaction conditions, the influence of different catalysts on the reaction was first investigated (entries 1-8), and finally catalyst C1 was determined as the best catalyst. Under the action of C2 catalyst, the α-allyl alkylation product was obtained. , and then investigated the effect of solvent on the reaction (entries 9-12), and finally determined that anhydrous toluene was the best solvent, the reaction temperature was 25 °C, and the catalyst dosage was 10 mol%.

典型催化剂C1合成路线,采用反应方程式表示如下:The synthesis route of typical catalyst C1 is represented by the reaction equation as follows:

Figure RE-GDA0003704228850000041
Figure RE-GDA0003704228850000041

氮气保护下,在15mL圆底烧瓶中,将1.0g 2-氨基环己醇A加入20mL二氯甲烷溶解,然后滴加3,5-双三氟甲基异硫1.84mL,快速点板进行监测。反应完全后,旋干柱层析,采用二氯甲烷/甲醇=60/1洗脱,得到中间体B,收率 81%。Under nitrogen protection, in a 15mL round bottom flask, add 1.0g of 2-aminocyclohexanol A to 20mL of dichloromethane to dissolve, then dropwise add 1.84mL of 3,5-bistrifluoromethylisosulfide, and quickly monitor the plate . After the completion of the reaction, spin-dried column chromatography, eluted with dichloromethane/methanol=60/1, to obtain Intermediate B in a yield of 81%.

氮气保护下,在15mL圆底烧瓶中,将2.0g中间体B加入30mL二氯甲烷溶解后,依次加入EDC 0.903mL和DMAP 315.2mg,再加入1.56g二苯基膦苯甲酸,室温反应8h,点板监测反应完毕。加水淬灭,二氯甲烷萃取,干燥旋干,柱层析得到白色固体催化剂C1,收率78%,熔点168.3-169.2℃。Under nitrogen protection, in a 15 mL round-bottom flask, 2.0 g of intermediate B was added to 30 mL of dichloromethane to dissolve, then 0.903 mL of EDC and 315.2 mg of DMAP were added in sequence, and then 1.56 g of diphenylphosphine benzoic acid was added, and the reaction was carried out at room temperature for 8 h. The dot plate monitoring reaction is completed. Quenching by adding water, extracting with dichloromethane, drying and spin drying, column chromatography to obtain a white solid catalyst C1, the yield is 78%, and the melting point is 168.3-169.2°C.

1H NMR(400MHz,CDCl3)δ8.46(s,1H),8.17-8.08(m,1H),7.90(s,2H),7.59(s,1H),7.41(pd,J=7.5,1.7Hz,2H),7.37-7.17(m,9H),7.12(t,J=7.4Hz,2H),6.90 (td,J=4.8,2.3Hz,1H),4.91(td,J=9.9,4.2Hz,1H),2.30(s,1H),1.92-1.09(m, 8H). 1 H NMR (400MHz, CDCl 3 ) δ 8.46 (s, 1H), 8.17-8.08 (m, 1H), 7.90 (s, 2H), 7.59 (s, 1H), 7.41 (pd, J=7.5, 1.7 Hz,2H),7.37-7.17(m,9H),7.12(t,J=7.4Hz,2H),6.90(td,J=4.8,2.3Hz,1H),4.91(td,J=9.9,4.2Hz , 1H), 2.30(s, 1H), 1.92-1.09(m, 8H).

13C NMR(100MHz,CDCl3)δ181.2,168.5,140.7,139.6(d,J=21.3Hz),136.7(d, J=4.6Hz),134.2,134.0,133.6(d,J=16.6Hz),132.8,131.8(q,J=33.5Hz), 131.3,129.3,129.1,128.9,128.8,128.7,123.2(q,J=272.8Hz),118.4,76.0, 57.7,31.4,30.5,24.0. 13 C NMR (100 MHz, CDCl 3 ) δ 181.2, 168.5, 140.7, 139.6 (d, J=21.3 Hz), 136.7 (d, J=4.6 Hz), 134.2, 134.0, 133.6 (d, J=16.6 Hz), 132.8 ,131.8(q,J=33.5Hz),131.3,129.3,129.1,128.9,128.8,128.7,123.2(q,J=272.8Hz),118.4,76.0,57.7,31.4,30.5,24.0.

19F NMR(376MHz,CDCl3)δ-62.90.31P NMR(162MHz,CDCl3)δ-4.24. HRMS(ESI)calcd.for C34H30F6O2N2PS([M+H]+):675.1664,found:675.1666. 19 F NMR (376 MHz, CDCl 3 ) δ-62.90. 31 P NMR (162 MHz, CDCl 3 ) δ-4.24. HRMS (ESI) calcd. for C 34 H 30 F 6 O 2 N 2 PS ([M+H] + ):675.1664,found:675.1666.

实施例1Example 1

将Morita-Baylis-Hillman碳酸酯1(1mmol,1.0eq)和催化剂C1(7.6mg,0.01mmol,0.1eq)溶解在超干甲苯(5.0mL)中,然后将4-叔丁基-2-三氟甲基噁唑-5(2H)-酮2(1.5mmol,1.5eq)。将反应混合物在室温搅拌72h,TLC监测原料完全反应后,减压除去溶剂后直接快速硅胶柱层析(石油醚/乙酸乙酯=1/50- 1/20)分离纯化得到无色油状产物3aa,收率为82%;HPLC CHIRALPAK OD- H,n-Hexane/2-prop anol=96/4,flow rate=0.8mL/min,λ=210nm,retention time: 9.166min(major),4.717min(minor);97%ee,dr=10:1;[α]30 D=-25.8(c 1.5, CHCl3);1H NMR(600MHz,CDCl3)δ7.34–7.08(m,5H),6.60(s,1H),6.48(s,1H), 5.11(s,1H),3.67(s,3H),1.13(s,9H);13C NMR(100MHz,CDCl3)δ175.0,166.4, 161.4,135.3,132.9,130.9,130.7,128.5,128.4,121.8(q,J=286.3Hz),100.9(q,J= 29.9Hz),52.7,47.4,35.0,26.3;19F NMR(565MHz,CDCl3)δ-75.08;HRMS(ESI)calcd.for C19H20F3O4N[M+H]+:384.14 17,found:384.1422.Morita-Baylis-Hillman carbonate 1 (1 mmol, 1.0 eq) and catalyst C1 (7.6 mg, 0.01 mmol, 0.1 eq) were dissolved in ultra-dry toluene (5.0 mL), followed by 4-tert-butyl-2-tris Fluoromethyloxazol-5(2H)-one 2 (1.5 mmol, 1.5 eq). The reaction mixture was stirred at room temperature for 72 h. After monitoring the complete reaction of the raw materials by TLC, the solvent was removed under reduced pressure, and the solvent was directly separated and purified by flash silica gel column chromatography (petroleum ether/ethyl acetate=1/50-1/20) to obtain a colorless oily product 3aa , the yield was 82%; HPLC CHIRALPAK OD-H, n-Hexane/2-propanol=96/4, flow rate=0.8mL/min, λ=210nm, retention time: 9.166min(major), 4.717min( minor); 97% ee, dr=10:1; [α] 30 D = -25.8 (c 1.5, CHCl 3 ); 1 H NMR (600 MHz, CDCl 3 ) δ 7.34-7.08 (m, 5H), 6.60 (s,1H), 6.48(s,1H), 5.11(s,1H), 3.67(s,3H), 1.13(s,9H); 13 C NMR (100 MHz, CDCl 3 ) δ 175.0, 166.4, 161.4, 135.3 , 132.9, 130.9, 130.7, 128.5, 128.4, 121.8 (q, J=286.3 Hz), 100.9 (q, J= 29.9 Hz), 52.7, 47.4, 35.0, 26.3; 19 F NMR (565 MHz, CDCl 3 )δ- 75.08; HRMS(ESI) calcd. for C 19 H 20 F 3 O 4 N[M+H] + : 384.14 17, found: 384.1422.

实施例2Example 2

Figure RE-GDA0003704228850000051
Figure RE-GDA0003704228850000051

将Morita-Baylis-Hillman碳酸酯1b(1mmol,1.0eq)和催化剂C1(7.6mg,0.01mmol,0.1eq)溶解在超干甲苯(5.0mL)中,然后将4-叔丁基-2-三氟甲基噁唑-5(2H)-酮2(1.5mmol,1.5eq)。将反应混合物在室温搅拌72h,TLC监测原料完全反应后,减压除去溶剂后直接快速硅胶柱层析(石油醚/乙酸乙酯=1/50- 1/20)分离纯化得到无色油状产物3ab,收率为75%;HPLC CHIRALPAK OD- H+IG,n-Hexane/2-propanol=96/4,flow rate=0.8mL/min,λ=210nm,retention time:16.448min(major),20.390min(minor);91%ee,dr=8:1;[α]30 D=-88.1(c 1.5, CHCl3);1H NMR(400MHz,CDCl3)δ7.37–7.19(m,2H),7.06(t,J=7.8Hz,2H), 6.64(s,1H),6.46(s,1H),5.70(s,1H),3.75(s,3H),1.25(s,9H);13C NMR(150 MHz,CDCl3)δ175.1,166.1,161.4,161.1(d,J=249.9Hz),135.1,131.4,131.0,130.3(d,J=7.9Hz),124.4(d,J=31.0Hz),123.6(d,J=4.2Hz),121.6(q,J=286.1 Hz),121.0(d,J=14.1Hz),116.1(d,J=23.1Hz),100.8(q,J=30.2Hz),52.7,38.8, 35.1,26.4;19F NMR(376MHz,CDCl3)δ–75.61,–114.70;HRMS(ESI)calcd.for C19H19F4O4N([M+H]+):402.1323,found:402.1318.Morita-Baylis-Hillman carbonate 1b (1 mmol, 1.0 eq) and catalyst C1 (7.6 mg, 0.01 mmol, 0.1 eq) were dissolved in ultra-dry toluene (5.0 mL), followed by 4-tert-butyl-2-tris Fluoromethyloxazol-5(2H)-one 2 (1.5 mmol, 1.5 eq). The reaction mixture was stirred at room temperature for 72 h. After monitoring the complete reaction of the raw materials by TLC, the solvent was removed under reduced pressure, and the solvent was directly separated and purified by flash silica gel column chromatography (petroleum ether/ethyl acetate=1/50-1/20) to obtain a colorless oily product 3ab , the yield was 75%; HPLC CHIRALPAK OD-H+IG, n-Hexane/2-propanol=96/4, flow rate=0.8mL/min, λ=210nm, retention time: 16.448min(major), 20.390min (minor); 91% ee, dr=8:1; [α] 30 D = -88.1 (c 1.5, CHCl 3 ); 1 H NMR (400 MHz, CDCl 3 ) δ 7.37-7.19 (m, 2H), 7.06(t, J=7.8Hz, 2H), 6.64(s, 1H), 6.46(s, 1H), 5.70(s, 1H), 3.75(s, 3H), 1.25(s, 9H); 13 C NMR (150 MHz, CDCl 3 )δ175.1, 166.1, 161.4, 161.1 (d, J=249.9 Hz), 135.1, 131.4, 131.0, 130.3 (d, J=7.9 Hz), 124.4 (d, J=31.0 Hz), 123.6 (d, J=4.2 Hz), 121.6 (q, J=286.1 Hz), 121.0 (d, J=14.1 Hz), 116.1 (d, J=23.1 Hz), 100.8 (q, J=30.2 Hz), 52.7 , 38.8, 35.1, 26.4; 19 F NMR (376MHz, CDCl 3 ) δ–75.61,–114.70; HRMS (ESI) calcd. for C 19 H 19 F 4 O 4 N([M+H] + ): 402.1323, found:402.1318.

实施例3Example 3

Figure RE-GDA0003704228850000061
Figure RE-GDA0003704228850000061

将Morita-Baylis-Hillman碳酸酯1c(1mmol,1.0eq)和催化剂C1(7.6mg,0.01mmol,0.1eq)溶解在超干甲苯(5.0mL)中,然后将4-叔丁基-2-三氟甲基噁唑-5(2H)-酮2(1.5mmol,1.5eq)。将反应混合物在室温搅拌72h,TLC监测原料完全反应后,减压除去溶剂后直接快速硅胶柱层析(石油醚/乙酸乙酯=1/50- 1/20)分离纯化得到无色油状产物3ac,收率为91%;HPLC CHIRALPAK OD- H+IG,n-Hexane/2-propanol=96/4,flow rate=0.8mL/min,λ=210nm,retention time:14.735min(major),17.525min(minor);99%ee,dr=12:1;[α]30 D=-24.9(c 1.5,CHCl3);1H NMR(400MHz,CDCl3)δ7.16(t,J=7.6Hz,1H),7.09–6.98(m, 3H),6.66(s,1H),6.54(s,1H),5.14(s,1H),3.75(s,3H),2.30(s,3H),1.21(s,9H);13C NMR(100MHz,CDCl3)δ174.9,166.5,161.4,137.9,135.3,132.8,131.4, 130.8,129.2,128.2,127.9,121.8(q,J=286.0Hz),100.9(q,J=29.8Hz),52.7,47.4, 35.0,26.3,21.5;19F NMR(376MHz,CDCl3)δ-75.10;HRMS(ESI)calcd.for C20H22F3O4N([M+H]+):398.1574,found:398.1578.Morita-Baylis-Hillman carbonate 1c (1 mmol, 1.0 eq) and catalyst C1 (7.6 mg, 0.01 mmol, 0.1 eq) were dissolved in ultra-dry toluene (5.0 mL), followed by 4-tert-butyl-2-tris Fluoromethyloxazol-5(2H)-one 2 (1.5 mmol, 1.5 eq). The reaction mixture was stirred at room temperature for 72 h. After monitoring the complete reaction of the raw materials by TLC, the solvent was removed under reduced pressure, and the solvent was directly separated and purified by flash silica gel column chromatography (petroleum ether/ethyl acetate=1/50-1/20) to obtain a colorless oily product 3ac , the yield is 91%; HPLC CHIRALPAK OD-H+IG, n-Hexane/2-propanol=96/4, flow rate=0.8mL/min, λ=210nm, retention time: 14.735min(major), 17.525min (minor); 99% ee, dr=12:1; [α] 30 D = -24.9 (c 1.5, CHCl 3 ); 1 H NMR (400 MHz, CDCl 3 ) δ 7.16 (t, J=7.6 Hz, 1H), 7.09–6.98(m, 3H), 6.66(s, 1H), 6.54(s, 1H), 5.14(s, 1H), 3.75(s, 3H), 2.30(s, 3H), 1.21(s , 9H); 13 C NMR (100 MHz, CDCl 3 ) δ 174.9, 166.5, 161.4, 137.9, 135.3, 132.8, 131.4, 130.8, 129.2, 128.2, 127.9, 121.8 (q, J=286.0 Hz), 100.9 (q, J =29.8Hz), 52.7, 47.4, 35.0, 26.3, 21.5; 19 F NMR (376 MHz, CDCl 3 ) δ-75.10; HRMS (ESI) calcd. for C 20 H 22 F 3 O 4 N ([M+H] + ):398.1574,found:398.1578.

实施例4Example 4

Figure RE-GDA0003704228850000062
Figure RE-GDA0003704228850000062

将Morita-Baylis-Hillman碳酸酯1d(1mmol,1.0eq)和催化剂C1(7.6mg,0.01mmol,0.1eq)溶解在超干甲苯(5.0mL)中,然后将4-叔丁基-2-三氟甲基噁唑-5(2H)-酮2(1.5mmol,1.5eq)。将反应混合物在室温搅拌72h,TLC监测原料完全反应,减压除去溶剂直接快速硅胶柱层析(石油醚/乙酸乙酯=1/50-1/20)分离纯化得到无色油状产物3ad,收率为92%;HPLC CHIRALPAK OD-H+IG,n- Hexane/2-propa nol=96/4,flow rate=0.8mL/min,λ=210nm,retention time: 15.550min(major),25.067min(minor);98%ee,dr=11:1;[α]30 D=-35.9(c 1.5, CHCl3);1H NMR(400MHz,CDCl3)δ7.24–7.17(m,1H),7.01–6.95(m,1H),6.97– 6.89(m,1H),6.69(s,1H),6.54(s,1H),5.49(s,1H),3.79(s,3H),1.21(s,9H);13C NMR(100MHz,CDCl3)δ175.1,166.1,161.5,135.8,135.5,131.7,129.8,129.0, 127.2,126.6,121.6(q,J=285.7Hz),100.4(q,J=29.8Hz),52.8,42.6,35.0,26.2;19F NMR(376MHz,CDCl3)δ-75.10;HRMS(ESI)calcd.for C17H18F3O4NS ([M+H]+):390.0981,found:390.0988.Morita-Baylis-Hillman carbonate 1d (1 mmol, 1.0 eq) and catalyst C1 (7.6 mg, 0.01 mmol, 0.1 eq) were dissolved in ultra-dry toluene (5.0 mL), followed by 4-tert-butyl-2-tris Fluoromethyloxazol-5(2H)-one 2 (1.5 mmol, 1.5 eq). The reaction mixture was stirred at room temperature for 72 h, TLC monitored the complete reaction of the raw materials, and the solvent was removed under reduced pressure to separate and purify directly by flash silica gel column chromatography (petroleum ether/ethyl acetate=1/50-1/20) to obtain a colorless oily product 3ad, which was obtained. HPLC CHIRALPAK OD-H+IG, n-Hexane/2-propa nol=96/4, flow rate=0.8mL/min, λ=210nm, retention time: 15.550min(major), 25.067min( minor); 98% ee, dr=11:1; [α] 30 D = -35.9 (c 1.5, CHCl 3 ); 1 H NMR (400 MHz, CDCl 3 ) δ 7.24-7.17 (m, 1H), 7.01 –6.95(m,1H),6.97- 6.89(m,1H),6.69(s,1H),6.54(s,1H),5.49(s,1H),3.79(s,3H),1.21(s,9H) ); 13 C NMR (100 MHz, CDCl 3 ) δ 175.1, 166.1, 161.5, 135.8, 135.5, 131.7, 129.8, 129.0, 127.2, 126.6, 121.6 (q, J=285.7 Hz), 100.4 (q, J=29.8 Hz) , 52.8, 42.6, 35.0, 26.2; 19 F NMR (376MHz, CDCl 3 ) δ-75.10; HRMS (ESI) calcd. for C 17 H 18 F 3 O 4 NS ([M+H] + ): 390.0981, found :390.0988.

实施例5:Embodiment 5:

Figure RE-GDA0003704228850000071
Figure RE-GDA0003704228850000071

将Morita-Baylis-Hillman碳酸酯1e(1mmol,1.0eq)和催化剂C1(7.6mg,0.01mmol,0.1eq)溶解在超干甲苯(5.0mL)中,然后将4-叔丁基-2-三氟甲基噁唑-5(2H)-酮2(1.5mmol,1.5eq)。将反应混合物在室温搅拌72h,TLC监测原料完全反应,减压除去溶剂直接快速硅胶柱层析(石油醚/乙酸乙酯=1/50-1/20) 分离纯化得到无色油状产物3ae,收率为92%;HPLC CHIRALPAK OD-H+IG, n-Hexane/2-prop anol=96/4,flow rate=0.8mL/min,λ=210nm,retention time: 14.127min(major),16.605min(minor);99%ee,dr=10:1;[α]30 D=-26.4(c 1.5, CHCl3);1H NMR(400MHz,CDCl3)δ7.26(s,5H),6.65(s,1H),6.50(s,1H),5.18 (s,1H),4.18(tt,J=7.3,3.5Hz,2H),1.26(t,J=7.1Hz,3H),1.21(s,9H);13CNMR (150MHz,CDCl3)δ174.9,165.9,161.4,135.6,133.1,130.7,130.5,128.6,128.4,121.8(q,J=286.2Hz),100.9(q,J=29.9Hz),61.7,47.3,35.0,26.3,14.2;19F NMR(376MHz,CDCl3)δ-75.14;HRMS(ESI)calcd.for C20H22F3O4N([M+H]+): 398.1574,found:398.1577.Morita-Baylis-Hillman carbonate 1e (1 mmol, 1.0 eq) and catalyst C1 (7.6 mg, 0.01 mmol, 0.1 eq) were dissolved in ultra-dry toluene (5.0 mL), followed by 4-tert-butyl-2-tris Fluoromethyloxazol-5(2H)-one 2 (1.5 mmol, 1.5 eq). The reaction mixture was stirred at room temperature for 72 h, TLC monitored the complete reaction of the raw materials, the solvent was removed under reduced pressure, and the solvent was directly separated and purified by flash silica gel column chromatography (petroleum ether/ethyl acetate=1/50-1/20) to obtain a colorless oily product 3ae, which was obtained. The rate was 92%; HPLC CHIRALPAK OD-H+IG, n-Hexane/2-propanol=96/4, flow rate=0.8mL/min, λ=210nm, retention time: 14.127min(major), 16.605min( minor); 99% ee, dr=10:1; [α] 30 D = -26.4 (c 1.5, CHCl 3 ); 1 H NMR (400 MHz, CDCl 3 ) δ 7.26 (s, 5H), 6.65 (s ,1H),6.50(s,1H),5.18(s,1H),4.18(tt,J=7.3,3.5Hz,2H),1.26(t,J=7.1Hz,3H),1.21(s,9H) ; 13 CNMR (150MHz, CDCl 3 ) δ 174.9, 165.9, 161.4, 135.6, 133.1, 130.7, 130.5, 128.6, 128.4, 121.8 (q, J=286.2 Hz), 100.9 (q, J=29.9 Hz), 61.7, 47.3 , 35.0, 26.3, 14.2; 19 F NMR (376 MHz, CDCl 3 ) δ-75.14; HRMS (ESI) calcd. for C 20 H 22 F 3 O 4 N ([M+H] + ): 398.1574, found: 398.1577 .

实施例6:Embodiment 6:

Figure RE-GDA0003704228850000072
Figure RE-GDA0003704228850000072

将Morita-Baylis-Hillman碳酸酯1f(1mmol,1.0eq)和催化剂C1(7.6mg,0.01mmol,0.1eq)溶解在超干甲苯(5.0mL)中,然后将4-叔丁基-2-三氟甲基噁唑-5(2H)-酮2(1.5mmol,1.5equiv)。将反应混合物在室温搅拌72h,TLC监测原料完全反应后,减压除去溶剂直接快速硅胶柱层析(洗脱剂石油醚/乙酸乙酯=1/50-1/20)分离纯化得到无色油状产物3af,收率为92%;99%ee,dr=12:1; HPLC CHIRAL PAK OD-H+IG,n-Hexane/2-propanol=96/4,flow rate=0.8 mL/min,λ=210nm,retention time:16.695min(major),21.775min(minor);[α]30 D=-32.4(c 1.5,CHCl3);1H NMR(600MHz,CDCl3)δ7.24(dd,J=5.1,3.0Hz, 1H),7.18(d,J=3.0Hz,1H),7.03–6.96(m,1H),6.62(s,1H),6.37(s,1H),5.34(s, 1H),3.78(s,3H),1.22(s,9H).13C NMR(100MHz,CDCl3)δ175.1,166.1,161.5,135.8,135.5,131.7,129.8,129.0,127.2,126.6,121.6(q,J=285.7Hz),100.4(q,J=29.8Hz),52.8,42.6,35.0,26.2.19F NMR(565MHz,CDCl3)δ-75.35;HRMS(ESI) calcd.forC17H18F3O4NS([M+H]+):390.0981,found:390.0984.Morita-Baylis-Hillman carbonate 1f (1 mmol, 1.0 eq) and catalyst C1 (7.6 mg, 0.01 mmol, 0.1 eq) were dissolved in ultra-dry toluene (5.0 mL), followed by 4-tert-butyl-2-tris Fluoromethyloxazol-5(2H)-one 2 (1.5 mmol, 1.5 equiv). The reaction mixture was stirred at room temperature for 72 h, after TLC monitoring the complete reaction of the raw materials, the solvent was removed under reduced pressure and the solvent was directly separated and purified by flash silica gel column chromatography (eluent petroleum ether/ethyl acetate=1/50-1/20) to obtain a colorless oil Product 3af, yield 92%; 99% ee, dr=12:1; HPLC CHIRAL PAK OD-H+IG, n-Hexane/2-propanol=96/4, flow rate=0.8 mL/min, λ= 210nm, retention time: 16.695min (major), 21.775min (minor); [α] 30 D=-32.4 (c 1.5, CHCl 3 ); 1 H NMR (600MHz, CDCl 3 )δ7.24 (dd, J= 5.1, 3.0Hz, 1H), 7.18(d, J=3.0Hz, 1H), 7.03–6.96(m, 1H), 6.62(s, 1H), 6.37(s, 1H), 5.34(s, 1H), 3.78(s, 3H), 1.22(s, 9H). 13 C NMR (100 MHz, CDCl 3 ) δ 175.1, 166.1, 161.5, 135.8, 135.5, 131.7, 129.8, 129.0, 127.2, 126.6, 121.6 (q, J=285.7 Hz), 100.4 (q, J=29.8 Hz), 52.8, 42.6, 35.0, 26.2. 19 F NMR (565 MHz, CDCl 3 ) δ-75.35; HRMS (ESI) calcd. for C 17 H 18 F 3 O 4 NS ( [M+H] + ):390.0981,found:390.0984.

以上实施例描述了本发明的基本原理、主要特征及优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明原理的范围下,本发明还会有各种变化和改进,这些变化和改进均落入本发明保护的范围内。The above embodiments describe the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited by the above-mentioned embodiments. The above-mentioned embodiments and descriptions only illustrate the principle of the present invention. Without departing from the scope of the principle of the present invention, the present invention will also have various Variations and improvements all fall within the scope of the present invention.

Claims (8)

1.一种合成光学活性三氟甲基丙烯酸酯类化合物的方法,其特征在于,包括如下步骤:以MBH碳酸酯1和噁唑酮2为原料,在L-叔亮氨酸衍生手性双官能团叔胺脲-膦类催化剂存在下,经过不对称烯丙基烷基化反应,得到三氟甲基丙烯酸酯类化合物3;反应方程式如下:1. a method for synthesizing optically active trifluoromethacrylate compounds, is characterized in that, comprises the steps: with MBH carbonate 1 and oxazolone 2 as raw materials, in L-tertiary leucine derivation chiral bicarbonate In the presence of a functional group tertiary amine urea-phosphine catalyst, through asymmetric allyl alkylation, trifluoromethacrylate compound 3 is obtained; the reaction equation is as follows:
Figure FDA0003595586200000011
Figure FDA0003595586200000011
其中:R1选自卤素、C1-C4烷基、C1-C4烷氧基、噻吩基;R2选自C1-C4烷基。Wherein: R 1 is selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, thienyl; R 2 is selected from C1-C4 alkyl.
2.根据权利要求1所述合成光学活性三氟甲基丙烯酸酯类化合物的方法,其特征在于:R1选自2-F、3-Me、2-噻吩基、3-噻吩基;R2选自Me、Et。2. The method for synthesizing optically active trifluoromethacrylate compounds according to claim 1, characterized in that: R 1 is selected from 2-F, 3-Me, 2-thienyl, 3-thienyl; R 2 Selected from Me, Et. 3.根据权利要求1所述合成光学活性三氟甲基丙烯酸酯类化合物的方法,其特征在于:催化剂选自C1-C8,具体结构式如下:3. the method for synthesizing optically active trifluoromethacrylate compounds according to claim 1, is characterized in that: catalyzer is selected from C1-C8, and concrete structural formula is as follows:
Figure FDA0003595586200000012
Figure FDA0003595586200000012
4.根据权利要求3所述合成光学活性三氟甲基丙烯酸酯类化合物的方法,其特征在于:催化剂选自C1或C6。4. The method for synthesizing optically active trifluoromethacrylate compounds according to claim 3, wherein the catalyst is selected from C1 or C6. 5.根据权利要求1所述合成光学活性三氟甲基丙烯酸酯类化合物的方法,其特征在于:所述MBH碳酸酯1、噁唑酮2与催化剂摩尔比为1:1-1.5:0.05-0.10。5. The method for synthesizing optically active trifluoromethacrylate compounds according to claim 1, wherein the molar ratio of the MBH carbonate 1, the oxazolone 2 and the catalyst is 1:1-1.5:0.05- 0.10. 6.根据权利要求1所述合成光学活性三氟甲基丙烯酸酯类化合物的方法,其特征在于:反应温度为0-30℃。6 . The method for synthesizing optically active trifluoromethacrylate compounds according to claim 1 , wherein the reaction temperature is 0-30° C. 7 . 7.根据权利要求1所述合成光学活性三氟甲基丙烯酸酯类化合物的方法,其特征在于:反应在空气氛围下进行。7. The method for synthesizing an optically active trifluoromethacrylate compound according to claim 1, wherein the reaction is carried out in an air atmosphere. 8.根据权利要求1-7任意一项所述合成光学活性三氟甲基丙烯酸酯类化合物的方法,其特征在于:反应在有机溶剂中进行,反应溶剂选自甲苯、二氯甲烷、四氢呋喃、均三甲苯、氯苯、五氟苯、间二甲苯、邻二甲苯或乙醚。8. The method for synthesizing optically active trifluoromethacrylate compounds according to any one of claims 1-7, wherein the reaction is carried out in an organic solvent, and the reaction solvent is selected from the group consisting of toluene, dichloromethane, tetrahydrofuran, Mesitylene, chlorobenzene, pentafluorobenzene, m-xylene, o-xylene or ether.
CN202210393810.2A 2022-04-14 2022-04-14 Method for synthesizing optically active trifluoromethyl acrylate compound Pending CN114835655A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210393810.2A CN114835655A (en) 2022-04-14 2022-04-14 Method for synthesizing optically active trifluoromethyl acrylate compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210393810.2A CN114835655A (en) 2022-04-14 2022-04-14 Method for synthesizing optically active trifluoromethyl acrylate compound

Publications (1)

Publication Number Publication Date
CN114835655A true CN114835655A (en) 2022-08-02

Family

ID=82565668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210393810.2A Pending CN114835655A (en) 2022-04-14 2022-04-14 Method for synthesizing optically active trifluoromethyl acrylate compound

Country Status (1)

Country Link
CN (1) CN114835655A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0386760A (en) * 1989-08-30 1991-04-11 Sumitomo Bakelite Co Ltd Photosensitive resin composition
US20050020652A1 (en) * 2001-11-30 2005-01-27 Gibson Tracey Ann Peroxisome proliferator activated receptor agonists
JP2005206587A (en) * 2003-12-26 2005-08-04 Central Glass Co Ltd Process for producing 1,1-bis (trifluoromethyl) -1,3-diols acrylic ester
WO2021097057A1 (en) * 2019-11-12 2021-05-20 Genzyme Corporation 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity
CN112898217A (en) * 2020-01-14 2021-06-04 河南师范大学 Trifluoromethyl oxazolone-containing compound, preparation method thereof and application thereof in anticancer drugs
US20220041602A1 (en) * 2019-01-29 2022-02-10 Novostar Pharmaceuticals, Ltd. Polycyclic compound inhibiting mnk1 and mnk2
CN114605361A (en) * 2022-04-14 2022-06-10 河南师范大学 A kind of method for synthesizing γ-hydroxy-γ-perfluoromethylbutenolide compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0386760A (en) * 1989-08-30 1991-04-11 Sumitomo Bakelite Co Ltd Photosensitive resin composition
US20050020652A1 (en) * 2001-11-30 2005-01-27 Gibson Tracey Ann Peroxisome proliferator activated receptor agonists
JP2005206587A (en) * 2003-12-26 2005-08-04 Central Glass Co Ltd Process for producing 1,1-bis (trifluoromethyl) -1,3-diols acrylic ester
US20220041602A1 (en) * 2019-01-29 2022-02-10 Novostar Pharmaceuticals, Ltd. Polycyclic compound inhibiting mnk1 and mnk2
WO2021097057A1 (en) * 2019-11-12 2021-05-20 Genzyme Corporation 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity
CN112898217A (en) * 2020-01-14 2021-06-04 河南师范大学 Trifluoromethyl oxazolone-containing compound, preparation method thereof and application thereof in anticancer drugs
CN114605361A (en) * 2022-04-14 2022-06-10 河南师范大学 A kind of method for synthesizing γ-hydroxy-γ-perfluoromethylbutenolide compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BO ZHU, ET AL.: "Synthesis of γ-hydroxy-γ-perfluoroalkyl butenolides and exocyclic double bond butanolides via regioselective allylic alkylations of MBH carbonates with 2-perfluoroalkyl-oxazol-5(2H)-ones", 《ORG. CHEM, FRONT.》, vol. 9, pages 2955 - 2962 *

Similar Documents

Publication Publication Date Title
CN107698590B (en) A method for the synthesis of chiral five-membered carbocyclic purine nucleosides by asymmetric [3+2] cyclization
CN100432083C (en) Phosphorus-oxazoline ligand with spiro backbone and its uses in asymmetrical catalytic hydrogenation
CN115010644B (en) A kind of preparation method of 2,3-disubstituted indoline compounds
CN108947894A (en) Novel biaryl structure chirality N- methylpyridoxal catalyst and its synthesis and application
CN108558692B (en) A kind of preparation method of amide compound
CN113200933B (en) Method for synthesizing optically active benzocarboxylate compound by asymmetric addition reaction
CN112174842B (en) Method for preparing (S) -3-amino-2-benzyl propionic acid
CN106748917B (en) A kind of chiral sulfenamide ligand and its preparation method and application
CN114835655A (en) Method for synthesizing optically active trifluoromethyl acrylate compound
CN110317201B (en) Asymmetric synthesis method of (S, S) -2, 8-diazabicyclo [4,3,0] nonane
CN108863884B (en) Method for synthesizing conjugated nitroene substituted series derivatives by using DAST reagent as elimination reagent
CN108558882B (en) Method for synthesizing chiral five-membered carbocyclic purine nucleoside through [3+2] cycloaddition based on allenoic acid ester
CN115215814A (en) Synthetic method of isoxazolidine compounds
CN113416162B (en) Double-chiral binaphthyl O-N-N tridentate ligand and preparation method thereof
CN114292277A (en) Indoline tetrahydropyrane compound and preparation method thereof
KR101087498B1 (en) Binaphthol aldehyde derivative and preparation method thereof
CN115322151A (en) Copper-catalyzed synthesis of chiral multi-stereocenter pyrazolidine compounds
CN110156730B (en) Synthesis method of chiral tricyclic benzofuran compound
CN103694157B (en) A kind of method of preparing chirality alpha-chloro aziridine
CN112442042B (en) Preparation method of spiro indole compound
CN108129348B (en) Nitrine trifluoromethoxy compound and its synthetic method
CN111793017A (en) A kind of preparation method of lactam compound
CN113620795B (en) Method for synthesizing benzocycloheptenone compounds
CN112851568B (en) A kind of synthetic method of 3-hydroxy-2-piperidinecarboxylic acid compound and its hydrochloride
CN106831522B (en) Lactam compound and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220802

WD01 Invention patent application deemed withdrawn after publication